About Astellas

Philosophy

The Astellas Group’s business philosophy has three elements — raison d'être, mission and beliefs. This business philosophy expresses the company’s aim...

Read More

Message from CEO

Astellas is a pharmaceutical company that is committed to turning innovative science into medical solutions that bring value and hope to patients worl...

Governance

The Astellas business philosophy is expressed through our Raison d'être, Mission and Beliefs. Our Raison d'etre is to contribute toward improving the...

History

Astellas was established in 2005 through merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical CO., Ltd. and has a rich history sp...

Board of Directors

Directors are elected at the Annual Shareholders Meeting for a term of one year. The Board of Directors meets once per month, as a general rule, and i...

Product Introductions

We are committed to research and development of products to turn innovative science into value for patients.

Top Management

The Executive Committee discusses important matters of management across Astellas. It is chaired by the Representative Director, President and CEO, an...

Read More
Financial Information

Review our consolidated business results, forecasts and financial data, etc.

Access Accelerated

Astellas participates in Access Accelerated. Access Accelerated is a first-of-its-kind, multi-stakeholder collaboration focused on improving Non-Communicable Disease (NCD) care. Involving 22 biopharmaceutical companies, the initiative works with partners such as World Bank Group and the Union for International Cancer Control to help overcome a variety of access barriers to NCD medicines in low-income and lower-middle income countries. Access Accelerated will support multi-stakeholder dialogue and begin on-the-ground work to improve NCD prevention, diagnosis and treatment.

Therapeutic Areas

To continue to make an ever-more- positive and meaningful difference in the lives of people with unmet medical needs, we concentrate our focus in therapeutic areas where our resources, expertise and technologies are greatest. Our focused therapeutic areas for research are urology, oncology, immunology, nephrology and neuroscience, as well as in new therapeutic areas such as muscle diseases and ophthalmology.